This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gleave, M. E. Articles by Chung, L. W. K. Search for Related Content PubMed PubMed Citation Articles by Gleave, M. E. Articles by Chung, L. W. K.

Serum Prostate Specific Antigen Levels in Mice Bearing Human Prostate LNCaP Tumors Are Determined by Tumor Volume and Endocrine and Growth Factors¹

Urology Research Laboratory, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

The ability of prostate-specific antigen (PSA) to predict tumor volume and stage in patients with prostate cancer would be improved if factors regulating its production and clearance were better defined. A thorough understanding of the pharmacokinetics (regulation of production, metabolism, and excretion) of PSA has been precluded, however, by the absence of an in vivo animal model. The purposes of this study are to develop a murine model for evaluating PSA pharmacokinetics in vivo and to assess factors that influence PSA production in vitro. The human prostate cancer cell line, LNCaP, was chosen because it is androgen sensitive and PSA positive. Although LNCaP cells are usually nontumorigenic when inoculated s.c. in athymic mice, coinoculation of 1 x 10⁴ LNCaP cells with 1 x 10⁶ human bone fibroblasts reliably produces PSA-secreting carcinomas. This LNCaP model provides accurate correlation between tumor volume and serum PSA levels (r = 0.94) and demonstrates that tumor volume and androgens are codeterminants of circulating PSA levels. Following castration, serum PSA levels decrease rapidly up to 8-fold and increase up to 20-fold following androgen supplementation, without detectable castration-induced tumor cell death or concomitant changes in tumor volume. Serum PSA levels increase 0.24 ng/ml/mm³ of tumor, which is approximately 5-fold less than that estimated for humans. Most likely this reduced PSA index (PSA:tumor volume ratio) results from a 7-fold faster clearance of PSA in athymic mice than in humans; other than this shorter half-life, PSA elimination in the murine model appears similar to that in humans, with both following first-order kinetics characteristic of a two-compartment model. Interestingly, following prolonged growth (>21 days) in castrate hosts, LNCaP tumors are capable of adapting to an androgen-deprived environment whereby LNCaP tumors regain the ability to secrete PSA in amounts similar to the precastrate state.

In LNCaP cells, androgens increase PSA mRNA levels 4-fold in vivo and in vitro. PSA mRNA expression is also altered by various growth factors. Changes in PSA production induced by androgens and growth factors do not always parallel changes in LNCaP cell growth rate induced by these factors, suggesting that PSA production occurs independently of cell growth rate and may be influenced by various interrelated factors, including hormonal and stromal milieu. Observations from this murine model suggest that androgens and tumor volume are independent determinants of serum PSA levels and imply that decreases in circulating PSA following antiandrogen therapy may not always reflect a corresponding reduction in tumor volume.

¹ This work was supported by Grants DK-38649 and CA 56307.

² To whom requests for reprints should be addressed.

Received 7/24/91. Accepted 1/ 6/92.

This article has been cited by other articles:

				J. A. Locke, E. S. Guns, A. A. Lubik, H. H. Adomat, S. C. Hendy, C. A. Wood, S. L. Ettinger, M. E. Gleave, and C. C. Nelson Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer Cancer Res., August 1, 2008; 68(15): 6407 - 6415. [Abstract] [Full Text] [PDF]

				A. Zoubeidi, A. Zardan, E. Beraldi, L. Fazli, R. Sowery, P. Rennie, C. Nelson, and M. Gleave Cooperative Interactions between Androgen Receptor (AR) and Heat-Shock Protein 27 Facilitate AR Transcriptional Activity Cancer Res., November 1, 2007; 67(21): 10455 - 10465. [Abstract] [Full Text] [PDF]

				C. Cai, C.-L. Hsieh, J. Omwancha, Z. Zheng, S.-Y. Chen, J.-L. Baert, and L. Shemshedini ETV1 Is a Novel Androgen Receptor-Regulated Gene that Mediates Prostate Cancer Cell Invasion Mol. Endocrinol., August 1, 2007; 21(8): 1835 - 1846. [Abstract] [Full Text] [PDF]

				D. R. Cochrane, Z. Wang, M. Muramaki, M. E. Gleave, and C. C. Nelson Differential Regulation of Clusterin and Its Isoforms by Androgens in Prostate Cells J. Biol. Chem., January 26, 2007; 282(4): 2278 - 2287. [Abstract] [Full Text] [PDF]

				W.-C. Huang, D. Wu, Z. Xie, H. E. Zhau, T. Nomura, M. Zayzafoon, J. Pohl, C.-L. Hsieh, M. N. Weitzmann, M. C. Farach-Carson, et al. {beta}2-Microglobulin Is a Signaling and Growth-Promoting Factor for Human Prostate Cancer Bone Metastasis. Cancer Res., September 15, 2006; 66(18): 9108 - 9116. [Abstract] [Full Text] [PDF]

				B. Dekel, S. Metsuyanim, K. M. Schmidt-Ott, E. Fridman, J. Jacob-Hirsch, A. Simon, J. Pinthus, Y. Mor, J. Barasch, N. Amariglio, et al. Multiple Imprinted and Stemness Genes Provide a Link between Normal and Tumor Progenitor Cells of the Developing Human Kidney. Cancer Res., June 15, 2006; 66(12): 6040 - 6049. [Abstract] [Full Text] [PDF]

				P. Rocchi, E. Beraldi, S. Ettinger, L. Fazli, R. L. Vessella, C. Nelson, and M. Gleave Increased Hsp27 after Androgen Ablation Facilitates Androgen-Independent Progression in Prostate Cancer via Signal Transducers and Activators of Transcription 3-Mediated Suppression of Apoptosis Cancer Res., December 1, 2005; 65(23): 11083 - 11093. [Abstract] [Full Text] [PDF]

				A. So, S. Sinnemann, D. Huntsman, L. Fazli, and M. Gleave Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo Mol. Cancer Ther., December 1, 2005; 4(12): 1837 - 1849. [Abstract] [Full Text] [PDF]

				M. S. Bhandari, J. Crook, and M. Hussain Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice? J. Clin. Oncol., November 10, 2005; 23(32): 8212 - 8218. [Abstract] [Full Text] [PDF]

				B. J.C. Eigl, S. E. Eggener, J. Baybik, S. Ettinger, K. N. Chi, C. Nelson, Z. Wang, and M. E. Gleave Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4905 - 4911. [Abstract] [Full Text] [PDF]

				C.-p. Chuu, R. A. Hiipakka, J. Fukuchi, J. M. Kokontis, and S. Liao Androgen Causes Growth Suppression and Reversion of Androgen-Independent Prostate Cancer Xenografts to an Androgen-Stimulated Phenotype in Athymic Mice Cancer Res., March 15, 2005; 65(6): 2082 - 2084. [Abstract] [Full Text] [PDF]

				Q. Wu, K. Esuvaranathan, and R. Mahendran Monitoring the Response of Orthotopic Bladder Tumors to Granulocyte Macrophage Colony-Stimulating Factor Therapy Using the Prostate-Specific Antigen Gene as a Reporter Clin. Cancer Res., October 15, 2004; 10(20): 6977 - 6984. [Abstract] [Full Text] [PDF]

				S. L. Ettinger, R. Sobel, T. G. Whitmore, M. Akbari, D. R. Bradley, M. E. Gleave, and C. C. Nelson Dysregulation of Sterol Response Element-Binding Proteins and Downstream Effectors in Prostate Cancer during Progression to Androgen Independence Cancer Res., March 15, 2004; 64(6): 2212 - 2221. [Abstract] [Full Text] [PDF]

				S. Kiyama, K. Morrison, T. Zellweger, M. Akbari, M. Cox, D. Yu, H. Miyake, and M. E. Gleave Castration-Induced Increases in Insulin-Like Growth Factor-Binding Protein 2 Promotes Proliferation of Androgen-independent Human Prostate LNCaP Tumors Cancer Res., July 1, 2003; 63(13): 3575 - 3584. [Abstract] [Full Text] [PDF]

				R. E. Bakin, D. Gioeli, E. A. Bissonette, and M. J. Weber Attenuation of Ras Signaling Restores Androgen Sensitivity to Hormone-refractory C4-2 Prostate Cancer Cells Cancer Res., April 15, 2003; 63(8): 1975 - 1980. [Abstract] [Full Text] [PDF]

				M. D. Sadar, V. A. Akopian, and E. Beraldi Characterization of a New in Vivo Hollow Fiber Model for the Study of Progression of Prostate Cancer to Androgen Independence Mol. Cancer Ther., June 1, 2002; 1(8): 629 - 637. [Abstract] [Full Text] [PDF]

				D. Kim, C. W. Gregory, F. S. French, G. J. Smith, and J. L. Mohler Androgen Receptor Expression and Cellular Proliferation During Transition from Androgen-Dependent to Recurrent Growth after Castration in the CWR22 Prostate Cancer Xenograft Am. J. Pathol., January 1, 2002; 160(1): 219 - 226. [Abstract] [Full Text] [PDF]

				M. R. McDevitt, D. Ma, L. T. Lai, J. Simon, P. Borchardt, R. K. Frank, K. Wu, V. Pellegrini, M. J. Curcio, M. Miederer, et al. Tumor Therapy with Targeted Atomic Nanogenerators Science, November 16, 2001; 294(5546): 1537 - 1540. [Abstract] [Full Text] [PDF]

				T. Nickerson, F. Chang, D. Lorimer, S. P. Smeekens, C. L. Sawyers, and M. Pollak In Vivo Progression of LAPC-9 and LNCaP Prostate Cancer Models to Androgen Independence Is Associated with Increased Expression of Insulin-like Growth Factor I (IGF-I) and IGF-I Receptor (IGF-IR) Cancer Res., August 1, 2001; 61(16): 6276 - 6280. [Abstract] [Full Text] [PDF]

				S. C. Dixon, K. B. Knopf, and W. D. Figg The Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents Pharmacol. Rev., March 1, 2001; 53(1): 73 - 92. [Abstract] [Full Text] [PDF]

				J. H. Pinthus, T. Waks, D. G. Schindler, A. Harmelin, J. W. Said, A. Belldegrun, J. Ramon, and Z. Eshhar WISH-PC2: A Unique Xenograft Model of Human Prostatic Small Cell Carcinoma Cancer Res., December 1, 2000; 60(23): 6563 - 6567. [Abstract] [Full Text]

				M. R. McDevitt, E. Barendswaard, D. Ma, L. Lai, M. J. Curcio, G. Sgouros, A. M. Ballangrud, W.-H. Yang, R. D. Finn, V. Pellegrini, et al. An {{alpha}}-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer Cancer Res., November 1, 2000; 60(21): 6095 - 6100. [Abstract] [Full Text]

				J. K. Jackson, M. E. Gleave, V. Yago, E. Beraldi, W. L. Hunter, and H. M. Burt The Suppression of Human Prostate Tumor Growth in Mice by the Intratumoral Injection of a Slow-Release Polymeric Paste Formulation of Paclitaxel Cancer Res., August 1, 2000; 60(15): 4146 - 4151. [Abstract] [Full Text]

				H. Miyake, C. Nelson, P. S. Rennie, and M. E. Gleave Overexpression of Insulin-Like Growth Factor Binding Protein-5 Helps Accelerate Progression to Androgen-Independence in the Human Prostate LNCaP Tumor Model through Activation of Phosphatidylinositol 3'-Kinase Pathway Endocrinology, June 1, 2000; 141(6): 2257 - 2265. [Abstract] [Full Text] [PDF]

				H. Miayake, A. Tolcher, and M. E. Gleave Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides J Natl Cancer Inst, January 5, 2000; 92(1): 34 - 41. [Abstract] [Full Text] [PDF]

				M. Gleave, A. Tolcher, H. Miyake, C. Nelson, B. Brown, E. Beraldi, and J. Goldie Progression to Androgen Independence Is Delayed by Adjuvant Treatment with Antisense Bcl-2 Oligodeoxynucleotides after Castration in the LNCaP Prostate Tumor Model Clin. Cancer Res., October 1, 1999; 5(10): 2891 - 2898. [Abstract] [Full Text] [PDF]

				H. Miyake, A. Tolcher, and M. E. Gleave Antisense Bcl-2 Oligodeoxynucleotides Inhibit Progression to Androgen-Independence after Castration in the Shionogi Tumor Model Cancer Res., August 1, 1999; 59(16): 4030 - 4034. [Abstract] [Full Text] [PDF]

				T. Nickerson, H. Miyake, M. E. Gleave, and M. Pollak Castration-induced Apoptosis of Androgen-dependent Shionogi Carcinoma Is Associated with Increased Expression of Genes Encoding Insulin-like Growth Factor-binding Proteins Cancer Res., July 1, 1999; 59(14): 3392 - 3395. [Abstract] [Full Text] [PDF]

				J. Lin, R. M. Adam, E. Santiestevan, and M. R. Freeman The Phosphatidylinositol 3'-kinase Pathway Is a Dominant Growth Factor-activated Cell Survival Pathway in LNCaP Human Prostate Carcinoma Cells Cancer Res., June 1, 1999; 59(12): 2891 - 2897. [Abstract] [Full Text] [PDF]

				A. M. Evens, T. M. Lestingi, and J. D. Bitran Intermittent Androgen Suppression as a Treatment for Prostate Cancer: A Review Oncologist, December 1, 1998; 3(6): 419 - 423. [Abstract] [Full Text]

				J. M. Kokontis, N. Hay, and S. Liao Progression of LNCaP Prostate Tumor Cells during Androgen Deprivation: Hormone-Independent Growth, Repression of Proliferation by Androgen, and Role for p27Kip1 in Androgen-Induced Cell Cycle Arrest Mol. Endocrinol., July 1, 1998; 12(7): 941 - 953. [Abstract] [Full Text]